Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ACE-031 for the Treatment of Duchenne Muscular Dystrophy

Drug

ACE-031

Company / Licensee

Acceleron Pharma

Therapy Class

A recombinant fusion protein

Product Description

Activin receptor type IIB

Current Indication

Duchenne Muscular Dystrophy (DMD)

Market Sector

CNS

Current Status

Phase II
Expand
Close
Close
Close

Go Top